Compass Capital Management Inc. Takes Position in Thermo Fisher Scientific Inc. $TMO

Compass Capital Management Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 104,987 shares of the medical research company’s stock, valued at approximately $52,636,000. Thermo Fisher Scientific comprises 3.2% of Compass Capital Management Inc.’s portfolio, making the stock its 14th biggest holding.

Other institutional investors also recently bought and sold shares of the company. Legacy Wealth Managment LLC ID increased its stake in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $26,000. High Note Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $28,000. Finally, JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth approximately $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $590.00 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market cap of $218.15 billion, a PE ratio of 31.74, a P/E/G ratio of 2.39 and a beta of 0.84. The company’s fifty day simple moving average is $533.64 and its 200-day simple moving average is $508.36. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company earned $4.28 EPS. The firm’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Analyst Ratings Changes

Several equities analysts recently commented on TMO shares. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective for the company. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada boosted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Finally, KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 4,608 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 52,053 shares of company stock worth $30,643,589. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.